Vertex Pharmaceuticals Incorporated is a Massachusetts-based biotechnology company that develops and commercializes medicines for serious diseases, with its current commercial portfolio concentrated in cystic fibrosis treatments including TRIKAFTA/KAFTRIO, ALYFTREK, KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI, and CASGEVY for sickle cell disease and beta thalassemia. The company also has a pain medicine JOURNAVX approved and a pipeline candidate povetacicept in late-stage development for immunoglobulin A nephropathy and other indications. Vertex trades on the Nasdaq Global Select Market under the ticker VRTX and is incorporated in Massachusetts.

What is VRTX's DredgeCap risk score?

DredgeCap's AI analysis rates VRTX at 3.2/10 on the risk scale — Low risk. This score reflects dilution exposure, debt toxicity, liquidity position, and going-concern posture as disclosed in SEC filings.

Does VRTX have a going concern warning?

No current auditor going-concern warning is flagged in VRTX's SEC filings. Risk assessment is based on other filing-disclosed factors.

When did VRTX last file with the SEC?

VRTX's most recent SEC filing was a 8-K filed 2026-03-31. All filings are available on SEC EDGAR.

← VRTX Overview

8-KMay 4, 2026

VRTX — 8-K Filing

Track VRTX for Alerts

8-K Items Disclosed

Item 2.02 — Results of Operations and Financial Condition

Quarterly or annual earnings results released. Often paired with a press release as Exhibit 99.1.

Item 9.01 — Financial Statements and Exhibits

Press releases, exhibits, and supporting documents attached to this filing.

VRTX Filing Excerpt

vrtx-20260504UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-K CURRENT REPORTPursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934Date of Report (Date of earliest event reported) May 4, 2026 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter)Massachusetts000-1931904-3039129(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)50 Northern Avenue Boston, Massachusetts 02210 (Address of principal executive offices) (Zip Code)(617) 341-6100 (Registrant's telephone number, including area code)Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act…

Current DredgeCap Risk Profile

Risk Score

3.2/10

MODERATE

Dilution

1.8

Debt Toxicity

1.5

Going Concern

✓ Not flagged

The risk profile above reflects the latest cached DredgeCap analysis for VRTX. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open VRTX's company page.

What is a 8-K?

A current report disclosing a material event that occurred between regular reporting periods. Companies are required to file an 8-K within four business days of certain events including earnings releases, executive changes, acquisitions, debt obligations, restructurings, and material agreements. Each 8-K specifies one or more 'Items' identifying which event triggered the filing.

More on VRTX

The plain-language summary above is composed mechanically from the filing's reported numbers — no analysis or opinion. Form-type explainers and 8-K item descriptions are derived from SEC documentation. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.